ELICIO THERAPEUTICS
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses. The company was founded in 2011 and is based in Cambridge, Massachusetts.
ELICIO THERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.elicio.com
Total Employee:
11+
Status:
Active
Contact:
(617)945-2077
Email Addresses:
[email protected]
Total Funding:
163.91 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Sitelinks Search Box Microsoft Exchange Online Office 365 Mail
Similar Organizations
ReCor Medical
ReCor Medical has developed a unique therapeutic non-focused ultrasound system
Recludix Pharma
Recludix pharma is a developing platform to treat cancer patients.
Nimbus Therapeutics
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
Neukio Biotherapeutics
Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.
Vico Therapeutics
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.
VYNE Therapeutics
VYNE Therapeutics is a clinical late-stage biopharmaceutical company developing treatments associated with dermatologic conditions.
MindSciences
MindSciences develops and implements evidence-based mindfulness solutions that delight its customers.
Mersana Therapeutics
Mersana Therapeutics develops a biodegradable polymer platform Fleximer® which creates new and better medicines.
Actinium Pharmaceuticals
Actinium Pharmaceuticals develops alpha particle linked antibodies to treat cancer.
Avivomed
Avivomed engages in developing neuromodulation therapy intended to treat unmet clinical needs.
Alchemab Therapeutics
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Aratana Therapeutics
Aratana Therapeutics develops innovative therapies for the animal health industry.
Abcuro
Abcuro develops first-in-class immunotherapies to treat autoimmunity and cancer.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
AccenGen Therapeutics
Early stage therapeutics developing novel first-in-class anti-inflammatory medications
Endpoint Health
Precision Immunology Therapies
Elstar Therapeutics
Fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapeutics.
EverImmune
EverImmune provides therapeutic tools related to cancer.
7 Hills Pharma
7 Hills Pharma is developing novel immunotherapies for the treatment Of cancer.
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuC™ platform.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Tallac Therapeutics
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Tempo Therapeutics
Tempo Therapeutics develops materials that are immune stealth, minimally invasive, and precision-engineered for regenerative medicine.
Unleash Immuno Oncolytics
Unleashing the immune response to treat cancer.
Serenity Bioworks
Developing therapeutics derived from cellular stress pathways.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Spinal Cord Therapeutics GmbH
Spinal Cord Therapeutics GmbH develops treatments for spinal cord injury.
Dynomics
Molecules to restore heart function.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Domain Therapeutics
Domain Therapeutics develops small molecules targeting G-coupled protein receptors.
HbO2 Therapeutics
HbO2 Therapeutics develops and manufactures oxygen carrying solutions.
Iaso Therapeutics
Iaso Therapeutics develops vaccines to improve human health and cure diseases.
IDM Pharma
IDM develops immunotherapies for cancer
IMTherapeutics
IM Therapeutics develops personalized immuno-therapeutic drugs.
Inceptor Bio
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
GITR
GITR develops therapies to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.
GO Therapeutics
A new generation of cancer immunotherapy promise to change the paradigm of cancer treatment.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Glyscend
Glyscend develops a revolutionary approach to treating type 2 diabetes.
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Osmol Therapeutics
Osmol Therapeutics develops treatment to prevent chemotherapy-induced peripheral neuropathy.
Oncorus
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
Oxford Vacmedix
Develop therapeutic agents for the treatment of cancer .
OncoPep
OncoPep is a developer of a multi-peptide therapeutic vaccine to prevent the progression of cancer.
Zylö Therapeutics
Zylö Therapeutics offers an innovative sustained-release drug-delivery system.
Carrick Therapeutics
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.
Clade Therapeutics
Clade Therapeutics discovers and delivers next-generation cell medicines to improve the lives of patients.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
CODA Biotherapeutics
CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.
Click Therapeutics
Click Therapeutics delivers safe and effective digital treatments to patients in need.
PanTher Therapeutics
PanTher Therapeutics features treatment platform designed to enhance therapeutic response with minimal side effects.
Phico Therapeutics
Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Current Advisors List
Current Employees Featured
Founder
Investors List
Trend Investment Group
Trend Investment Group investment in Series B - Elicio Therapeutics
Livzon Pharmaceutical Group
Livzon Pharmaceutical Group investment in Series B - Elicio Therapeutics
Clal Biotechnology Industries
Clal Biotechnology Industries investment in Series B - Elicio Therapeutics
EFung Capital
EFung Capital investment in Series B - Elicio Therapeutics
Thynk Capital, LLC.
Thynk Capital, LLC. investment in Venture Round - Elicio Therapeutics
Access BridgeGap Ventures
Access BridgeGap Ventures investment in Venture Round - Elicio Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-12 | Elicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion of Dr. Peter DeMuth to Chief Scientific Officer |
Official Site Inspections
http://www.elicio.com Semrush global rank: 5.53 M Semrush visits lastest month: 1.54 K
- Host name: elicio.tempurl.host
- IP address: 45.76.164.42
- Location: Matawan United States
- Latitude: 40.4652
- Longitude: -74.2307
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07747
More informations about "Elicio Therapeutics"
Amplifying the Potential of Immunotherapies - Elicio
We are an exceptional team of leaders dedicated to creating profound and enduring change in immuno-oncology. With expertise in materials science, immunology, and oncology, we plan to …See details»
Elicio Therapeutics - Crunchbase Company Profile & Funding
Elicio Therapeutics may be growing as evidenced by its recent financial activities and research advancements. The company has secured significant private placement financing, with …See details»
Elicio Therapeutics - LinkedIn
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most ...See details»
Elicio Therapeutics - Overview, News & Similar companies
Who is Elicio Therapeutics. Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other …See details»
Elicio Therapeutics - Contacts, Employees, Board Members
Organization. Elicio Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Contacts 33. About. Elicio Therapeutics …See details»
Elicio Therapeutics - PitchBook
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its …See details»
AMP Platform Media and Resources | Elicio Therapeutics
Nov 7, 2024 BIOSPACE: Finally, Elicio Therapeutics is expected to present the first-ever data from the 7P formulation of its off-the-shelf cancer vaccine candidate, ELI-002 7P, targeting …See details»
Elicio Therapeutics Completes Reverse Merger and Provides a …
Jun 6, 2023 Elicio Therapeutics. Elicio completes reverse merger, becoming a publicly traded company on the Nasdaq stock exchange. Positive Phase 1 clinical data was recently …See details»
Elicio cancer vaccine boosts T-cell therapy response to tumors in …
Jan 29, 2024 Elicio has launched a phase 2 trial on a second formulation of ELI-002, dubbed ELI-002 7P, which targets the seven KRAS mutations found in a quarter of all solid cancers. …See details»
Elicio Therapeutics - Craft
Oct 28, 2024 Elicio Therapeutics (formerly known as Vedantra Pharmaceuticals) is an immuno-oncology company developing vaccines and immunotherapies for aggressive solid and …See details»
Elicio Therapeutics Announces Pricing of $11.5 Million …
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline …See details»
Elicio Therapeutics Secures a Total of $73 Million in Series B ...
Feb 17, 2021 Elicio’s lead Amphiphile vaccine, ELI-002, targeting KRAS-driven cancers will begin initial patient studies in solid tumor patients in the first quarter of 2021.See details»
Elicio Therapeutics to Present New Preliminary Data from the …
Apr 25, 2024 Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 …See details»
Governance Documents | Investor Resources for Elicio Therapeutics
The Board of Directors of Elicio Therapeutics Inc. (the “Company”) sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of …See details»
Investor Information and Resources | Elicio Therapeutics
Nov 13, 2024 Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates November 7, 2024 Elicio Therapeutics Presents Updated Translational …See details»
Elicio Therapeutics Reports 2023 Financial Results and Provides ...
BOSTON, March 29, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a …See details»
Elicio Therapeutics Reports First Quarter 2024 Financial Results …
May 15, 2024 Elicio Therapeutics, Inc. ELI-002 2P Phase 1 preliminary data published in Nature Medicine . ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS …See details»
Elicit: The AI Research Assistant
“A meta-analysis of 30 randomized, double-blind, placebo-controlled trials concluded that fish oil consumption can significantly reduce heart rate (Mozaffarian 2005).In particular, the effect was …See details»
Elicio Therapeutics Announces First Patient Dosed in Randomized …
Jan 11, 2024 Elicio Therapeutics Inc. The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations that drive 25% of all solid …See details»